Research has shown that prescribing anti-dementia drugs to patients could delay entry into a care homes by up to a year. The study, published in The Psychiatrist journal last month claimed that patients who took cholinesterase inhibitors, such as donepezil, galantamine, rivastigmine and memantine among the drugs which caused much controversy just a couple of years ago – could remain in their own homes for up to a year longer than patients who did not take the drugs.
Home LaingBuisson Newsletter Archives Care Markets Study reveals anti-dementia drugs may delay care home admission